ELI LILLY AND COMPANY Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
ELI LILLY AND COMPANY (LLY) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $12.70 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2025-10-30
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $12.70M.
- 2025-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $83.00M.
- 2025-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $102.60M.
- 2024-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $95.20M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2025-09-30 | $12.70M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $83.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $102.60M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $95.20M 10-K · filed 2025-02-19 |
| 2024-09-30 | $105.90M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $97.40M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $83.70M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $84.10M 10-K · filed 2024-02-21 |
| 2023-09-30 | $88.20M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $86.10M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $76.00M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $86.20M 10-K · filed 2023-02-22 |
| 2022-09-30 | $97.70M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $102.10M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $98.90M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $75.90M 10-K · filed 2022-02-23 |
| 2021-09-30 | $21.60M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $21.60M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $30.80M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $13.90M 10-K · filed 2021-02-17 |
| 2020-09-30 | $20.90M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $20.20M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $73.30M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $91.20M 10-K · filed 2020-02-19 |
| 2019-09-30 | $87.90M 10-Q · filed 2019-10-25 |
| 2019-06-30 | $76.30M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $99.30M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $86.80M 8-K · filed 2019-10-24 |
| 2018-09-30 | $74.70M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $88.00M 10-Q · filed 2018-07-25 |
| 2018-03-31 | $1.70B 10-Q · filed 2018-04-27 |
| 2017-12-31 | $1.49B 10-K · filed 2018-02-20 |
| 2017-09-30 | $3.21B 10-Q · filed 2017-10-27 |
| 2017-06-30 | $2.36B 10-Q · filed 2017-07-28 |
| 2017-03-31 | $886.60M 10-Q · filed 2017-05-01 |
| 2016-12-31 | $1.46B 10-K · filed 2017-02-21 |
| 2016-09-30 | $737.80M 10-Q · filed 2016-10-28 |
| 2016-06-30 | $696.80M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $687.40M 10-Q · filed 2016-04-29 |
| 2015-12-31 | $785.40M 10-K · filed 2016-02-19 |
| 2015-09-30 | $1.08B 10-Q · filed 2015-10-30 |
| 2015-06-30 | $915.40M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $1.07B 10-Q · filed 2015-04-30 |
| 2014-12-31 | $955.40M 10-K · filed 2015-02-19 |
| 2014-09-30 | $1.55B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $1.22B 10-Q · filed 2014-07-28 |
| 2014-03-31 | $1.10B 10-Q · filed 2014-04-28 |
| 2013-12-31 | $1.21B 10-K · filed 2014-02-19 |
| 2013-09-30 | $1.01B 10-Q · filed 2013-10-30 |
| 2013-06-30 | $924.50M 10-Q · filed 2013-07-26 |
| 2013-03-31 | $795.80M 10-Q · filed 2013-04-26 |
| 2012-12-31 | $1.67B 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |